Alnylam Pharmaceuticals Inc to Discuss Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran Conference Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals Conference Call to discuss top line results from the ILLUMINATE-A Phase III study of lumasiran. (Operator Instructions) Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company.
Good morning. I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Barry Greene, our President. Also joining us in the room and available for Q&A are Yvonne Greenstreet, our Chief Operating Officer; Jeff Poulton, our Chief Financial Officer; and Pritesh Gandhi, General Manager of the lumasiran program. For those of you participating via conference call, the slides, we have made available via webcast, can also be accessed by going to the investor page of our website,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
